Beneficial cardiopulmonary effects of pentoxifylline in experimental sepsis are lost once septic shock is established. 1994

P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
Department of Surgery, Medical College of Virginia, Richmond.

OBJECTIVE To determine the effects of pretreatment and posttreatment with pentoxifylline in a porcine model of gram-negative sepsis. METHODS Nonrandomized controlled trial. METHODS Young Yorkshire swine. METHODS Six groups of ventilated swine were studied for 5 hours. Group 1 swine (control, n = 8) received saline solution only. Group 2 swine (sepsis, n = 8) received a 1-hour infusion of Pseudomonas aeruginosa. Groups 3, 4, and 5 swine received the P aeruginosa infusion and a 20 mg/kg bolus followed by a 6 mg/kg per hour infusion of pentoxifylline. Group 3 swine (n = 6) received pentoxifylline prior to the onset of sepsis; group 4 swine (n = 6) received pentoxifylline at 1 hour and group 5 swine (n = 4) at 2 hours after the onset of the P aeruginosa infusion. Group 6 swine (control pentoxifylline, n = 3) received pentoxifylline only. METHODS Hemodynamic variables, neutrophil counts and CD18 expression, tumor necrosis factor activity, and arterial blood gases were measured hourly. Bronchoalveolar lavage was performed at 0 and 5 hours to measure neutrophil and protein content. RESULTS All variables remained unchanged in the control and control pentoxifylline groups. Both pretreatment and posttreatment with pentoxifylline significantly attenuated lung injury and improved arterial PaO2. The cardiac index was significantly improved by administration of pentoxifylline in groups 3 and 4. Administration of pentoxifylline to group 5 animals in established septic shock caused uncontrolled, fatal systemic hypotension in two of the four animals. Plasma tumor necrosis factor activity, blood polymorphonuclear leukocyte counts, and CD18 expression were unaffected by the administration of pentoxifylline. CONCLUSIONS Pentoxifylline protects against pulmonary and systemic hemodynamic derangements in fulminant sepsis and protects against pulmonary dysfunction. Pentoxifylline has a "therapeutic window" when given in established sepsis; if administration is delayed until overt septic shock occurs, it may then have deleterious effects.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D010431 Pentoxifylline A METHYLXANTHINE derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. Agapurin,BL-191,Oxpentifylline,Pentoxil,Torental,Trental,BL 191,BL191
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D012137 Respiratory System The tubular and cavernous organs and structures, by means of which pulmonary ventilation and gas exchange between ambient air and the blood are brought about. Respiratory Tract,Respiratory Systems,Respiratory Tracts,System, Respiratory,Tract, Respiratory
D001784 Blood Gas Analysis Measurement of oxygen and carbon dioxide in the blood. Analysis, Blood Gas,Analyses, Blood Gas,Blood Gas Analyses,Gas Analyses, Blood,Gas Analysis, Blood
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D002319 Cardiovascular System The HEART and the BLOOD VESSELS by which BLOOD is pumped and circulated through the body. Circulatory System,Cardiovascular Systems,Circulatory Systems

Related Publications

P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
February 1990, Critical care medicine,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
November 1990, Postgraduate medical journal,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 1997, Critical care medicine,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 1989, Journal of medicine,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 2019, Frontiers in pharmacology,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
August 2006, Critical care medicine,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 2010, Intensive care medicine,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
August 1990, Circulatory shock,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 1998, Research in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie,
P C Ridings, and A C Windsor, and H J Sugerman, and E Kennedy, and M M Sholley, and C R Blocher, and B J Fisher, and A A Fowler
January 1982, Circulatory shock,
Copied contents to your clipboard!